Dedicates upgraded National Centre for Disease Control, Delhi and a Temporary Regional Branch of NCDC to the nation
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
The company received gross proceeds of approximately US$1.7 million and net proceeds,
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Marks remarkable acceleration in innovation using AI technology
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
NEIAFMR to be developed as the national hub for folk medicine
The product is expected to be launched in December 2023
Furthering cell therapy ambition across oncology and autoimmune diseases
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Subscribe To Our Newsletter & Stay Updated
